Ledipasvir Export Market Intelligence: India's 60 Suppliers Shipping to 44 Countries — TransData Nexus 2026

Q: Who are the top ledipasvir exporters from India?

The top ledipasvir exporters from India are: 1. HETERO LABS LIMITED — $659.7K (58.1% market share); 2. MYLAN LABORATORIES LIMITED — $229.2K (20.2% market share); 3. ROYAL MEDICAL PRIVATE LIMITED — $29.0K (2.6% market share); 4. SACRED LEAVES PRIVATE LIMITED — $27.3K (2.4% market share); 5. OCEAN PHARMACEUTICAL — $24.9K (2.2% market share). Together they account for 85.5% of India's total ledipasvir export value.

Q: What is the total export value of ledipasvir from India?

The total export value of ledipasvir from India is $1.1M USD, recorded across 228 shipment transactions from 60 active exporters to 44 destination countries. The average shipment value is $5.0K.

Q: Which countries import ledipasvir from India?

India exports ledipasvir to 44 countries worldwide. The top importing countries are: KYRGYZSTAN (20.1% share, $228.2K), UZBEKISTAN (18.7% share, $211.7K), KENYA (17.4% share, $197.5K), KAZAKHSTAN (11.8% share, $134.1K), AZERBAIJAN (10.5% share, $119.4K). These five markets account for 78.5% of total export value.

Q: What is the HS code for ledipasvir exports from India?

The primary HS code for ledipasvir exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of ledipasvir exports from India?

The average unit price for ledipasvir exports from India is $44.03 USD per unit, with prices ranging from $0.01 to $196.20 depending on formulation, packaging, and order volume. The total market is valued at $1.1M across 228 shipments.

Q: Which ports handle ledipasvir exports from India?

The primary ports for ledipasvir exports from India are SAHAR AIR CARGO ACC (INBOM4) (32.9% of shipments), SAHAR AIR (17.5% of shipments), DELHI AIR CARGO ACC (INDEL4) (14.5% of shipments), DELHI AIR (8.3% of shipments), AHEMDABAD AIR (6.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of ledipasvir?

India is one of the world's leading exporters of ledipasvir due to its large base of 60 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports ledipasvir to 44 countries, demonstrating 23% global market coverage.

Q: What certifications do Indian ledipasvir exporters need?

Indian ledipasvir exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import ledipasvir from India?

There are 90 registered buyers importing ledipasvir from India, spread across 44 countries. The repeat buyer rate is 40.0%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top ledipasvir supplier from India?

HETERO LABS LIMITED is the leading ledipasvir exporter from India with a market share of 58.1% and total export value of $659.7K across 15 shipments. The top 5 suppliers together control 85.5% of total export value.

Suresh Sormare

Ledipasvir

India Pharmaceutical Trade Intelligence

$1.1M60 Suppliers44 CountriesHS 30049099

ExportsIndia → KYRGYZSTAN20.1%India → UZBEKISTAN18.7%

#1 Supplier: HETERO LABS

Ledipasvir Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Ledipasvir to the World

Between 2022 and 2026, India exported $1.1M worth of ledipasvir across 228 verified shipments to 44 countries — covering 23% of world markets in the Antiviral & HIV Medications segment. The largest destination is KYRGYZSTAN (20.1%). HETERO LABS LIMITED leads with a 58.1% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Ledipasvir export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Ledipasvir export data snapshot — $1.1M · 60 exporters · 44 countriesTransData Nexus · Indian Customs Data

Top Ledipasvir Exporters from India

60 active exporters · Ranked by export value

View all 60 →

Top Ledipasvir Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	HETERO LABS LIMITED	$659.7K	15	5	58.1%
2	MYLAN LABORATORIES LIMITED

Top Countries Importing Ledipasvir from India

44 destination markets · Ranked by import value

All 44 countries →

Top Countries Importing Ledipasvir from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	KYRGYZSTAN	$228.2K	20.1%
2	UZBEKISTAN	$211.7K	18.7%
3	KENYA	$197.5K	17.4%
4	KAZAKHSTAN	$134.1K	11.8%
5	AZERBAIJAN	$119.4K	10.5%
6	TURKEY	$76.6K	6.7%
7	MONGOLIA	$30.9K	2.7%
8	UNITED ARAB EMIRATES	$26.4K	2.3%
9	IRAQ	$20.8K	1.8%
10	POLAND	$14.9K	1.3%

KYRGYZSTAN is India's largest ledipasvir export destination, absorbing 20.1% of total exports worth $228.2K. The top 5 importing countries — KYRGYZSTAN, UZBEKISTAN, KENYA, KAZAKHSTAN, AZERBAIJAN — together account for 78.5% of India's total ledipasvir export value. The remaining 39 destination countries collectively receive the other 21.5%, indicating a focused distribution strategy targeting key markets.

Regulatory Landscape — Ledipasvir

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, the combination of ledipasvir and sofosbuvir is marketed under the brand name Harvoni. The FDA approved Harvoni on October 10, 2014, for the treatment of chronic HCV infection in adults. Subsequent approvals expanded its use to pediatric patients aged 12 and older on April 7, 2017, and to those aged 3 to 11 on August 28, 2019.

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for generic versions of ledipasvir/sofosbuvir, indicating the absence of generic competition in the U.S. market. Additionally, there are no current import alerts related to ledipasvir, suggesting compliance with FDA regulations by exporters. Given that 60 Indian exporters are actively involved in the international trade of ledipasvir, the absence of generic approvals in the U.S. presents a potential market opportunity for these manufacturers.

2EU & UK Regulatory Framework

The European Medicines Agency (EMA) granted marketing authorization for Harvoni on November 17, 2014, for the treatment of chronic HCV in adults and pediatric patients aged 3 years and above. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) adopted this authorization prior to Brexit. Post-Brexit, the MHRA continues to recognize EMA approvals unless specific changes are announced.

Manufacturers exporting ledipasvir to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA. These standards ensure product quality and safety, necessitating regular inspections and adherence to stringent manufacturing protocols.

3WHO Essential Medicines & Global Standards

Ledipasvir, in combination with sofosbuvir, is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The combination is also subject to WHO Prequalification, a program that assesses the quality, safety, and efficacy of medicinal products. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for manufacturers to meet global quality benchmarks.

4India Regulatory Classification

In India, ledipasvir is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, ledipasvir is not listed under the DPCO, allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international trade regulations.

5Patent & Exclusivity Status

The primary patent for the combination of ledipasvir and sofosbuvir expired in October 2024, concluding the exclusivity period. This expiration opens the market to generic competition, providing opportunities for Indian exporters to supply cost-effective alternatives to global markets.

6Recent Industry Developments

In June 2025, the EMA released revised bioequivalence guidelines for ledipasvir/sofosbuvir formulations, emphasizing the need for comprehensive studies to ensure therapeutic equivalence. (ema.europa.eu) In September 2025, the WHO updated its Essential Medicines List, reaffirming the inclusion of ledipasvir/sofosbuvir, highlighting its continued importance in HCV treatment protocols. In December 2025, the NPPA conducted a review of antiviral drug prices, including ledipasvir, to assess market trends and ensure affordability. In January 2026, the DGFT streamlined the export NOC process for pharmaceutical products, aiming to facilitate smoother international trade for Indian exporters. In February 2026, the CDSCO issued a notification reinforcing the requirement for bioequivalence studies for generic versions of ledipasvir/sofosbuvir, ensuring consistent therapeutic outcomes.

These developments reflect a dynamic regulatory environment, with ongoing efforts to balance innovation, accessibility, and quality in the pharmaceutical sector.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Ledipasvir

Retail & reference prices across 9 markets vs. India FOB export price of $44.03/unit

Global Price Benchmark for Ledipasvir across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	N/A	USD	The U.S. Food and Drug Administration (FDA) provides comprehensive information on drug approvals and labeling but does not publicly disclose pricing information.
United Kingdom	N/A	GBP	The National Health Service (NHS) Drug Tariff lists medications and their reimbursement prices; however, specific pricing for Ledipasvir/Sofosbuvir is not publicly available.
Germany	N/A	EUR	The European Medicines Agency (EMA) provides regulatory information on Harvoni but does not disclose pricing details. (ema.europa.eu)

Supply Chain Risk Assessment — Ledipasvir

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

Ledipasvir, an antiviral agent used in the treatment of hepatitis C, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the pharmaceutical raw material market.

The reliance on Chinese KSMs introduces significant supply chain vulnerabilities. For instance, in October 2025, the U.S. Pharmacopeia reported that 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting the global dependence on Chinese suppliers. Any disruptions in China's production capabilities, whether due to geopolitical tensions, environmental regulations, or other factors, can lead to substantial delays and increased costs in API manufacturing for drugs like Ledipasvir.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters account for 85.5% of Ledipasvir exports, with HETERO LABS LIMITED alone contributing 58.1% of the total export value. This high concentration poses a significant single-source risk, as any operational or regulatory issues faced by these key suppliers could disrupt the global supply chain for Ledipasvir.

Access Complete Ledipasvir Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 228 transactions across 44 markets.

Request Demo View Pricing

Frequently Asked Questions — Ledipasvir Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top ledipasvir exporters from India?

The leading ledipasvir exporters from India are HETERO LABS LIMITED, MYLAN LABORATORIES LIMITED, ROYAL MEDICAL PRIVATE LIMITED, and 11 others. HETERO LABS LIMITED leads with 58.1% market share ($659.7K). The top 5 suppliers together control 85.5% of total export value.

What is the total export value of ledipasvir from India?

The total export value of ledipasvir from India is $1.1M, recorded across 228 shipments from 60 active exporters to 44 countries. The average shipment value is $5.0K.

Which countries import ledipasvir from India?

India exports ledipasvir to 44 countries. The top importing countries are KYRGYZSTAN (20.1%), UZBEKISTAN (18.7%), KENYA (17.4%), KAZAKHSTAN (11.8%), AZERBAIJAN (10.5%), which together account for 78.5% of total export value.

What is the HS code for ledipasvir exports from India?

The primary HS code for ledipasvir exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Ledipasvir

Ledipasvir

How India Exports Ledipasvir to the World

Top Ledipasvir Exporters from India

Top Countries Importing Ledipasvir from India

Quick Facts

Related Antiviral & HIV Medications

Related Analysis

Need Details?

Regulatory Landscape — Ledipasvir

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Ledipasvir

Supply Chain Risk Assessment — Ledipasvir

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Ledipasvir Trade Intelligence

Frequently Asked Questions — Ledipasvir Exports from India

Who are the top ledipasvir exporters from India?

What is the total export value of ledipasvir from India?

Which countries import ledipasvir from India?

What is the HS code for ledipasvir exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of ledipasvir exports from India?

Which ports handle ledipasvir exports from India?

Why is India a leading exporter of ledipasvir?

What certifications do Indian ledipasvir exporters need?

How many buyers import ledipasvir from India?

What is the market share of the top ledipasvir exporter from India?

Analysis Methodology